Advanced Search

 

Study ID Status Title Patient Level Data
SAM40100 Completed Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS ® inhlaer 50/100mcg twice daily vs. FLIXOTIDE® inhaler 200mcg twice daily. Study Listed on ClinicalStudyDataRequest.com
SAM40101 Completed A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. Study Listed on ClinicalStudyDataRequest.com
SAM40104 Completed Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS® inhaler 50/100 mcg twice daily vs FLIXOTIDE® inhaler 200 mcg twice daily Study Listed on ClinicalStudyDataRequest.com
SAS10006 Completed A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the Diskus (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the Diskus Study Listed on ClinicalStudyDataRequest.com
SAS10007 Completed A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product Diskus (FP 250mcg/SALM 50mcg), FP/Salmeterol combination metered dose inhaler (MDI) (FP 110mcg/SALM 21mcg) containing the hydrofluoroalkane (HFA) propellant, GR106642X, and FP MDI (FP 110mcg) containing HFA propellant Study Listed on ClinicalStudyDataRequest.com
SAS10013 Completed An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
SAS10014 Completed A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects Study Listed on ClinicalStudyDataRequest.com
SAS10015 Completed A randomised, double-blind, double-dummy, cross-over comparison of the salmeterol/fluticasone propionate combination product (50/250mg strength) twice daily via one Diskus inhaler with salmeterol 50mg twice daily via one Diskus inhaler plus fluticasone propionate 250mg twice daily via a second Diskus inhaler in Japanese and Caucasian asthmatics Study Listed on ClinicalStudyDataRequest.com
SAS10016 Completed A 4-week, randomized, double-blind, placebo run-in, parallel-group study in pediatric subjects with asthma aged 4-11 years to examine the pharmacodynamics and pharmacokinetics of the fluticasone propionate (FP) and salmeterol (SALM) combination product administered twice daily via the Diskus (FP 100mcg/SALM 50mcg) and the FP Diskus (FP 100mcg) Study Listed on ClinicalStudyDataRequest.com
SAS10017 Completed Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Compare the Relative Bioavailability and Pharmacodymanics of Fluticasone Propionate from Two Batches of Seretide MDI with Different in vitro Characteristics Study Listed on ClinicalStudyDataRequest.com
SAS10019 Completed A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma Study Listed on ClinicalStudyDataRequest.com
SAS104449 Completed A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma Study Listed on ClinicalStudyDataRequest.com
SAS105519 Completed A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily Study Listed on ClinicalStudyDataRequest.com
SAS30017 Completed A Randomized, Double-Blind, Active-Controlled, Parallel-Group 12-Week Trial Evaluating the Safety and Efficacy of the 50/100mcg Salmeterol/Fluticasone Propionate DISKUS Combination Product twice daily Compared with Salmeterol 50mcg via DISKUS twice daily and Fluticasone Propionate 100mcg via DISKUS twice daily in Adult and Adolescent Subjects with Asthma on Short-Acting Beta2-Agonist Therapy Study Listed on ClinicalStudyDataRequest.com
SAS30019 Completed A multicentre, randomised, double-blind, double-dummy, parallel group study to compare salmeterol/fluticasone propionate combination 50/100mcg twice daily delivered via dry powder inhaler (Diskus/Accuhaler) or non-chlorofluorocarbon metered-dose inhaler in the treatment of children with asthma aged 4-11 years. Study Listed on ClinicalStudyDataRequest.com
SAS30021 Completed A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma Study Listed on ClinicalStudyDataRequest.com
SAS30022 Completed A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate 250mcg once daily versus fluticasone propionate/salmeterol 100/50mcg twice daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta agonist therapy Study Listed on ClinicalStudyDataRequest.com
SAS30023 Completed A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects Study Listed on ClinicalStudyDataRequest.com
SAS30024 Completed A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ... Study Listed on ClinicalStudyDataRequest.com
SAS30031 Completed A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg twice daily Versus Fluticasone Propionate DISKUS 100mcg twice daily in Symptomatic Pediatric Subjects (4-11 Years) With Asthma Study Listed on ClinicalStudyDataRequest.com
SAS30033 Completed An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age Study Listed on ClinicalStudyDataRequest.com
SAS30039 Completed A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE™/VIANI™/ADVAIR™) 50/250μg twice-daily with fluticasone propionate 250μg twice-daily, all via the DISKUS®/ACCUHALER® as initial maintenance therapy in moderate persistent asthma. Study Listed on ClinicalStudyDataRequest.com
SAS30040 Completed A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability ofsalmeterol/fluticasone propionate combination 50/100mcg twice daily with fluticasone propionate 250mcg twice daily, all via theDISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptomshave been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcgcombination twice-daily for 12 weeks Study Listed on ClinicalStudyDataRequest.com
SAS40020 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40021 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.